ArticleJournal of gastrointestinal cancer2025
Validation of tumor burden score as a prognostic factor in colorectal cancer liver metastases patients: a retrospective analysis.
Article in Journal of gastrointestinal cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Prognostic impact of tumour burden score on colorectal cancer liver metastasis survival following resection: a meta-analysis.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026Article
- Laparoscopic versus open minor liver resections of colorectal cancer liver metastases in a state at war: A prospective cohort study.Surgery open science · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeThe assessment of resectability in patients with colorectal cancer (CRC) and multiple liver metastases is primarily a technical decision. However, in cases with unfavourable tumor biology, the clinical benefit of surgery remains limited. Further research is needed to identify additional factors influencing oncological outcomes in these patients to better guide the decision-making process. The aim of this study was to investigate the association of tumor burden score (TBS) and oncological outcome in CRC patients with multiple bilobar metastases.
methodsFive hundred twenty-one consecutive patients who underwent liver resections for CRC liver metastases between January 2002 and January 2024 were identified from the National Cancer Institute (Kyiv, Ukraine) prospective database and analysed retrospectively.
resultsThe median and 5-year overall survival in cohorts with TBS clusters < 3, ≥ 3-9 and ≥ 9 was 116.2 months, 50.3 months and 29.7 months; and 75.7%, 42.4% and 41.6%, respectively (P < 0.001). TBS index has shown high prognostic specificity and sensitivity for postoperative morbidity with AUC 0.97 on the ROC curve. The multivariate Cox regression model has shown that the TBS clusters have a significant negative impact on overall survival particularly in cohorts with TBS ≥ 3-9 (HR: 2.8, 95% CI: 1.7-4.8, P = 0.0001) and TBS ≥ 9 (HR: 1.4, 95% CI: 1.31-1.46, P = 0.005).
conclusionIn this Ukranian population-based study of patients with resectable CRC liver metastases, high TBS was associated with poorer overall survival.
Indexed as
Identifiers
40366485What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.